How far has the stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) come to trade at their current price of $36.25, which gives it a market cap of $1.28B.
To trade now at $36.25, the stock has emerged from a 52-week low of $31.17%. But the current price also compares with the 52-week peak of $-50.53%.
The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum.
Recently, Puma Biotechnology, Inc. (NASDAQ:PBYI) announced that
The stock?s journey to the current price can be understood by looking at its performance from the last week down to the 12 months. The stock’s weekly performance stands at 18.27% and its monthly performance is -1.63%. For the quarter, the stock has moved -4.23% and for half-year it has shifted -9.60%. So far this year the stock has moved 22.34% and for the last 12 months it has moved 18.08%.
Studying simple moving averages also tell the stock’s journey thus far. The 20-Day Simple Moving Average is $2.60%, the 50-Day Simple Moving Average is $-3.25%, while the 200-Day Simple Moving Average is $-15.66%.
Puma Biotechnology, Inc.’s P/Cash for the most recent quarter is 6.59. For perspective, payout ratio provides insight into a company’s ability to sustain dividend distributions. As such, a lower payout ratio is preferred to a higher payout ratio is it implies a company is preserving more cash for investments and other needs that it releases to shareholders.
Puma Biotechnology’s shares jumped 13.46 percent to close at $36.25 a share on Wednesday. The stock traded between $31.10 and $37.45 on volume of 2.03 million shares traded. On May 17th, the company announced that an abstract on its drug candidate PB272, a potential treatment for HER2-positive breast cancer, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2nd to 6th in Chicago. Puma Biotechnology reported a GAAP net loss of $72.9 million, or $1.97 per share, for the first quarter of 2017, compared to a net loss $71.0 million, or $2.19 per share, for the same quarter a year ago. Puma had cash and cash equivalents of $105.1 million and marketable securities of $88.9 million, as of March 31st, 2017. Shares of Puma Biotechnology have gained approximately 18.08 percent year-to-date.